Rapid generation of sustainable HER2-specific T cell immunity in HER2 breast cancer patients using a degenerate HLA class II epitope vaccine

PURPOSE: HER2+ breast cancer patients benefit from trastuzumab-containing regimens with improved survival. Adaptive immunity, including cytotoxic T cell and antibody immunity, is critical to clinical efficacy of trastuzumab. Since helper T cells are central to the activation of these antitumor effec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Knutson, Keith L., Block, Matthew S., Norton, Nadine, Erskine, Courtney L., Hobday, Timothy J., Dietz, Allan B., Padley, Douglas J., Gustafson, Michael P., Puglisi-Knutson, Danell J., Mangskau, Toni K., Chumsri, Saranya, Dueck, Amylou C., Karyampudi, Lavakumar, Wilson, Glynn, Degnim, Amy
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7056565/
https://ncbi.nlm.nih.gov/pubmed/31757875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-2123
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados